Research map: Burden of illness of Duchenne muscular dystrophy in Belgium: A retrospective, descriptive, cross-sectional study

Back to the article

Papers in this map

  1. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management · David J. Birnkrant · 2018 · 1391 citations · Cited by this paper
  2. Minute-by minute gait variations during the 6-Minute walk test in subjects with myotonic dystrophy type 1 · 2026 · Related
  3. Duchenne muscular dystrophy · Dongsheng Duan · 2021 · 1350 citations · Cited by this paper
  4. Congenital myasthenic syndrome due to novel GFPT1 variant presenting with head drop and visual impairment: A case report · 2026 · Related
  5. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management · David J. Birnkrant · 2018 · 1193 citations · Cited by this paper
  6. Not only cross-sectional area: Echogenicity matters in nerve ultrasound studies of patients with motor multifocal neuropathy · 2026 · Related
  7. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis · Salvatore Crisafulli · 2020 · 510 citations · Cited by this paper
  8. Orofacial dysfunction in persons with congenital or childhood-onset neuromuscular disorders · 2026 · Related
  9. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study · Craig M. McDonald · 2017 · 488 citations · Cited by this paper
  10. Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis · 2026 · Related
  11. The burden of Duchenne muscular dystrophy · Erik Landfeldt · 2014 · 231 citations · Cited by this paper
  12. Developing endpoints for the cardiac burden in myotonic dystrophy type 1: A workshop report · 2026 · Related
  13. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene · Manuel Haas · 2014 · 161 citations · Cited by this paper
  14. Expanding repeats, expanding impact: Somatic instability in myotonic dystrophy type 1 · 2026 · Related
  15. Duchenne muscular dystrophy and caregiver burden: a systematic review · Erik Landfeldt · 2018 · 142 citations · Cited by this paper
  16. Effects of intermittent corticosteroids on scoliosis, bone density, and vertebral fractures in duchenne muscular dystrophy · 2026 · Related
  17. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany · Olivia Schreiber‐Katz · 2014 · 94 citations · Cited by this paper
  18. A qualitative study of the discrepancy between patient expectations and assessment practices in 5q-adult spinal muscular atrophy in France · 2026 · Related
  19. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe · Marianna Cavazza · 2016 · 88 citations · Cited by this paper
  20. IMU-based workspace area as a promising complementary tool to assess upper limb function in Neuromuscular diseases: A one-year follow-up · 2026 · Related
  21. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta‐analysis of disease progression rates in recent multicenter clinical trials · Craig M. McDonald · 2019 · 76 citations · Cited by this paper
  22. An EQ-5D-5L Value Set for Belgium · Nicolas Bouckaert · 2022 · 57 citations · Cited by this paper
  23. Duchenne muscular dystrophy: an updated review of common available therapies · Arash Salmaninejad · 2018 · 56 citations · Cited by this paper
  24. Gene Therapy for Muscular Dystrophy: Moving the Field Forward · Samiah A. Al-Zaidy · 2014 · 45 citations · Cited by this paper
  25. Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL · Donna Rowen · 2021 · 44 citations · Cited by this paper
  26. Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond · Dongsheng Duan · 2023 · 38 citations · Cited by this paper
  27. Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR) · Anna J. Roy · 2014 · 27 citations · Cited by this paper
  28. An EQ-5D-Y-3L Value Set for Belgium · Sarah Dewilde · 2022 · 23 citations · Cited by this paper
  29. Developing a Natural History Model for Duchenne Muscular Dystrophy · Jonathan Broomfield · 2023 · 23 citations · Cited by this paper
  30. Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study · Pedro Labisa · 2021 · 21 citations · Cited by this paper

Source: OpenAlex (CC0)